| scholarly article | Q13442814 |
| P50 | author | Cees van Nieuwkoop | Q47136125 |
| Jacobus Burggraaf | Q88913167 | ||
| Daniel Touw | Q89780595 | ||
| Jasper Stevens | Q38798939 | ||
| P2093 | author name string | Johan Willem Mouton | |
| Anneke Corinne Dijkmans | |||
| Erik Bert Wilms | |||
| Ingrid Maria Catharina Kamerling | |||
| Natalia Veneranda Ortiz Zacarías | |||
| P2860 | cites work | MurA (MurZ), the enzyme that catalyzes the first committed step in peptidoglycan biosynthesis, is essential in Escherichia coli | Q24671787 |
| Molecular Mechanisms and Clinical Impact of Acquired and Intrinsic Fosfomycin Resistance | Q26853135 | ||
| Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE | Q28276828 | ||
| Effects of fosfomycin and imipenem-cilastatin on the nephrotoxicity of vancomycin and cisplatin in rats | Q28374187 | ||
| Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America | Q29616084 | ||
| Isolation and characterization of mutations affecting the transport of hexose phosphates in Escherichia coli | Q30451453 | ||
| Fosfomycin for the treatment of infections caused by multidrug-resistant non-fermenting Gram-negative bacilli: a systematic review of microbiological, animal and clinical studies | Q33436519 | ||
| Synergy of fosfomycin with other antibiotics for Gram-positive and Gram-negative bacteria | Q33534711 | ||
| Emergence of fosfomycin-resistant isolates of Shiga-like toxin-producing Escherichia coli O26 | Q33976610 | ||
| Fosfomycin therapy for multiresistant Pseudomonas aeruginosa in cystic fibrosis | Q33982025 | ||
| Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum beta-lactamase producing, Enterobacteriaceae infections: a systematic review. | Q34096605 | ||
| Antibiotic abscess penetration: fosfomycin levels measured in pus and simulated concentration-time profiles | Q34123684 | ||
| The mechanism of action of fosfomycin (phosphonomycin) | Q34214482 | ||
| Antibiotic resistance-the need for global solutions | Q34386251 | ||
| Tackling antibiotic resistance | Q34390844 | ||
| Protective effect of fosfomycin on gentamicin-induced lipid peroxidation of rat renal tissue | Q44995115 | ||
| Mechanisms of intestinal absorption of the antibiotic, fosfomycin, in brush-border membrane vesicles in rabbits and humans. | Q45519834 | ||
| High fosfomycin concentrations in bone and peripheral soft tissue in diabetic patients presenting with bacterial foot infection. | Q45939590 | ||
| Fosfomycin for Pseudomonas-related exacerbations of cystic fibrosis | Q46429470 | ||
| Antimicrobial susceptibility of multidrug-resistant Gram negative bacteria to fosfomycin. | Q46795441 | ||
| Fosfomycin concentrations in serum and bile (author's transl) | Q50189861 | ||
| Synergy of fosfomycin with carbapenems, colistin, netilmicin, and tigecycline against multidrug-resistant Klebsiella pneumoniae, Escherichia coli, and Pseudomonas aeruginosa clinical isolates. | Q51017942 | ||
| Pharmacokinetic profile of fosfomycin trometamol. | Q51599099 | ||
| In vitro activity of colistin or sulbactam in combination with fosfomycin or imipenem against clinical isolates of carbapenem-resistant Acinetobacter baumannii producing OXA-23 carbapenemases. | Q54326122 | ||
| Pharmacokinetic and pharmacodynamic aspects of antimicrobial agents for the treatment of uncomplicated urinary tract infections. | Q54460259 | ||
| Fosfomycin monophosphate and fosfomycin diphosphate, two inactivated fosfomycin derivatives formed by gene products of fomA and fomB from a fosfomycin producing organism Streptomyces wedmorensis. | Q54589592 | ||
| Characterization of a Cys115 to Asp substitution in the Escherichia coli cell wall biosynthetic enzyme UDP-GlcNAc enolpyruvyl transferase (MurA) that confers resistance to inactivation by the antibiotic fosfomycin. | Q54590227 | ||
| Characterization of spontaneous fosfomycin (phosphonomycin)-resistant cells of Escherichia coli B in vitro | Q54621230 | ||
| Pharmacokinetics of fosfomycin | Q67540907 | ||
| Pharmacokinetic study of fosfomycin and its bioavailability | Q67540912 | ||
| Blood and urinary concentrations of fosfomycin as a function of the renal function value | Q67540922 | ||
| Pharmacokinetic profile of fosfomycin trometamol (Monuril) | Q68988795 | ||
| Pharmacokinetic comparison between fosfomycin and other phosphonic acid derivatives | Q70265679 | ||
| Pharmacokinetics of Phosphonomycin in Man I:Intravenous Administration | Q70617150 | ||
| The influence of uremia on the accessibility of phosphomycin into interstitial tissue fluid | Q71066593 | ||
| Antibacterial spectrum of fosfomycin trometamol | Q72282822 | ||
| Phosphonomycin, a New Antibiotic Produced by Strains of Streptomyces | Q72475705 | ||
| In-vitro activity of antimicrobial agent combinations against multiresistant Acinetobacter baumannii | Q73046683 | ||
| In vitro activity of fosfomycin combined with ceftazidime, imipenem, amikacin, and ciprofloxacin against Pseudomonas aeruginosa | Q73230024 | ||
| Fosfomycin Monophosphate and Fosfomycin Diphosphate, Two Inactivated Fosfomycin Derivatives Formed by Gene Products of fomA and fomB from a Fosfomycin Producing Organism Streptomyces wedmorensis. | Q78422728 | ||
| [Fosfomycin trometamol: multiple-dose regimen for the treatment of lower urinary tract infections] | Q79381413 | ||
| Fosfomycin resistance proteins: a nexus of glutathione transferases and epoxide hydrolases in a metalloenzyme superfamily | Q34482492 | ||
| 'Old' antibiotics for emerging multidrug-resistant bacteria | Q34565772 | ||
| Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship | Q34591740 | ||
| Penetration of fosfomycin into inflammatory lesions in patients with cellulitis or diabetic foot syndrome | Q34721887 | ||
| Fosfomycin: use beyond urinary tract and gastrointestinal infections | Q34774778 | ||
| Antimicrobial susceptibilities of commonly encountered bacterial isolates to fosfomycin determined by agar dilution and disk diffusion methods | Q35191584 | ||
| Fosfomycin versus meropenem in bacteraemic urinary tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli (FOREST): study protocol for an investigator-driven randomised controlled trial | Q35278325 | ||
| Comparative pharmacokinetics of tromethamine fosfomycin and calcium fosfomycin in young and elderly adults | Q35310871 | ||
| Fosfomycin kinetics after intravenous and oral administration to human volunteers | Q35671533 | ||
| Pharmacodynamics of fosfomycin: insights into clinical use for antimicrobial resistance | Q35960788 | ||
| Resistance to antibiotics: are we in the post-antibiotic era? | Q36282569 | ||
| Evaluation of three-dose fosfomycin tromethamine in the treatment of patients with urinary tract infections: an uncontrolled, open-label, multicentre study | Q37374128 | ||
| Clinical significance of the pharmacokinetic and pharmacodynamic characteristics of fosfomycin for the treatment of patients with systemic infections | Q37614630 | ||
| Fosfomycin: an old, new friend? | Q37633415 | ||
| Critical shortage of new antibiotics in development against multidrug-resistant bacteria-Time to react is now. | Q37857510 | ||
| Conserving antibiotics for the future: new ways to use old and new drugs from a pharmacokinetic and pharmacodynamic perspective | Q37858138 | ||
| The revival of fosfomycin | Q37938425 | ||
| The role of pharmacokinetics/pharmacodynamics in setting clinical MIC breakpoints: the EUCAST approach | Q37977530 | ||
| Fosfomycin: Absorption and Excretion | Q39130873 | ||
| Characterization of the fomA and fomB gene products from Streptomyces wedmorensis, which confer fosfomycin resistance on Escherichia coli. | Q39473127 | ||
| Distribution and antimicrobial activity of fosfomycin in the interstitial fluid of human soft tissues. | Q39475307 | ||
| Relationship between Fosfomycin Exposure and Amplification of Escherichia coli Subpopulations with Reduced Susceptibility in a Hollow-Fiber Infection Model | Q39704722 | ||
| Antibacterial activity of cefmetazole alone and in combination with fosfomycin against methicillin- and cephem-resistant Staphylococcus aureus | Q39851746 | ||
| Clinically relevant concentrations of fosfomycin combined with polymyxin B, tobramycin or ciprofloxacin enhance bacterial killing of Pseudomonas aeruginosa, but do not suppress the emergence of fosfomycin resistance. | Q40697349 | ||
| The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America | Q41445493 | ||
| Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. | Q41696128 | ||
| Role of ciprofloxacin in its synergistic effect with fosfomycin on drug-resistant strains of Pseudomonas aeruginosa | Q42170768 | ||
| Is fosfomycin a potential treatment alternative for multidrug-resistant gram-negative prostatitis? | Q42242522 | ||
| Extracellular concentrations of fosfomycin in lung tissue of septic patients | Q43130327 | ||
| Antimicrobial susceptibility of multidrug-resistant (MDR) and extensively drug-resistant (XDR) Enterobacteriaceae isolates to fosfomycin | Q43207954 | ||
| Intravenous fosfomycin for the treatment of nosocomial infections caused by carbapenem-resistant Klebsiella pneumoniae in critically ill patients: a prospective evaluation | Q43289024 | ||
| Fosfomycin: efficacy against infections caused by multidrug-resistant bacteria | Q43662701 | ||
| Degree of absorption, pharmacokinetics of fosfomycin trometamol and duration of urinary antibacterial activity | Q43805708 | ||
| Effectiveness of fosfomycin combined with other antimicrobial agents against multidrug-resistant Pseudomonas aeruginosa isolates using the efficacy time index assay | Q43961938 | ||
| Penetration of fosfomycin into cerebrospinal fluid across non-inflamed and inflamed meninges | Q44011977 | ||
| Does combination antimicrobial therapy reduce mortality in Gram-negative bacteraemia? A meta-analysis | Q44116286 | ||
| Fosfomycin: Laboratory Studies | Q44320155 | ||
| Target site penetration of fosfomycin in critically ill patients | Q44385715 | ||
| Effect of non-beta-lactam antibiotics on penicillin-binding protein synthesis of Enterococcus hirae ATCC 9790. | Q44467186 | ||
| Concentrations of fosfomycin in the cerebrospinal fluid of neurointensive care patients with ventriculostomy-associated ventriculitis. | Q44824183 | ||
| An increase in the antimicrobial activity in vitro of fosfomycin under anaerobic conditions | Q44923509 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 4 | |
| P577 | publication date | 2017-10-31 | |
| P1433 | published in | Antibiotics (Basel, Switzerland) | Q27725829 |
| P1476 | title | Fosfomycin: Pharmacological, Clinical and Future Perspectives | |
| P478 | volume | 6 |
| Q89669079 | Bloodstream infections in critically ill patients: an expert statement |
| Q88918474 | Cell-Wall Recycling of the Gram-Negative Bacteria and the Nexus to Antibiotic Resistance |
| Q57821217 | Community-Acquired Urinary Tract Infection by in the Era of Antibiotic Resistance |
| Q58756032 | Conserved collateral antibiotic susceptibility networks in diverse clinical strains of Escherichia coli |
| Q92311237 | Deciphering pharmacokinetics and pharmacodynamics of fosfomycin |
| Q58604628 | First Description of Colistin and Tigecycline-Resistant Producing KPC-3 Carbapenemase in Portugal |
| Q64886394 | Fosfomycin in antimicrobial stewardship programs. |
| Q64949904 | Fosfomycin in infections caused by multidrug-resistant Gram-negative pathogens. |
| Q64917427 | Fosfomycin in the pediatric setting: Evidence and potential indications. |
| Q64116187 | Fosfomycin: the characteristics, activity, and use in critical care |
| Q64886188 | New microbiological aspects of fosfomycin. |
| Q64945950 | New perspectives for reassessing fosfomycin: applicability in current clinical practice. |
| Q64898853 | Oral and intravenous fosfomycin in complicated urinary tract infections. |
| Q57297606 | Photo-Crosslinked Polymeric Matrix with Antimicrobial Functions for Excisional Wound Healing in Mice |
| Q90371794 | Recommendations for Systemic Antimicrobial Therapy in Fracture-Related Infection: A Consensus From an International Expert Group |
| Q59136944 | Swine Enteric Colibacillosis in Spain: Pathogenic Potential of ST10 and ST131 Isolates |
| Q89972749 | The frontiers of addressing antibiotic resistance in Neisseria gonorrhoeae |
| Q92500177 | Unexpected Activity of Oral Fosfomycin against Resistant Strains of Escherichia coli in Murine Pyelonephritis |
Search more.